GCTK

SEC source: 0001993078-25-000003 · primary_doc.xml · derivative · entry 4

Carter Erin Catherine · CIK 0001993078 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,055

Underlying: Common Stock, par value $0.001 per share · 4,055 shares

Expires 2035-10-03

F1 · derivative.exercise_date: Each option grant has a vesting commencement date of July 1 of the applicable calendar year and vests in 12 equal monthly installments over the 12-month period ending June 30 of the following year, subject to the reporting person's continued service to the Issuer through each vesting date.

SEC source: 0001993078-25-000003 · primary_doc.xml · nonDerivative · entry 3

Carter Erin Catherine · CIK 0001993078 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,148

SEC source: 0001323190-25-000003 · primary_doc.xml · derivative · entry 4

Balo Andrew K · CIK 0001323190 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,055

Underlying: Common Stock, par value $0.001 per share · 4,055 shares

Expires 2035-10-03

F1 · derivative.exercise_date: Each option grant has a vesting commencement date of July 1 of the applicable calendar year and vests in 12 equal monthly installments over the 12-month period ending June 30 of the following year, subject to the reporting person's continued service to the Issuer through each vesting date.

SEC source: 0001323190-25-000003 · primary_doc.xml · nonDerivative · entry 3

Balo Andrew K · CIK 0001323190 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,692

SEC source: 0001395781-25-000002 · primary_doc.xml · derivative · entry 4

Malave Luis · CIK 0001395781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,055

Underlying: Common Stock, par value $0.001 per share · 4,055 shares

Expires 2035-10-03

F1 · derivative.exercise_date: Each option grant has a vesting commencement date of July 1 of the applicable calendar year and vests in 12 equal monthly installments over the 12-month period ending June 30 of the following year, subject to the reporting person's continued service to the Issuer through each vesting date.

SEC source: 0001395781-25-000002 · primary_doc.xml · nonDerivative · entry 3

Malave Luis · CIK 0001395781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,058

SEC source: 0001993078-25-000003 · primary_doc.xml · nonDerivative · entry 2

Carter Erin Catherine · CIK 0001993078 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,762

SEC source: 0001323190-25-000003 · primary_doc.xml · nonDerivative · entry 2

Balo Andrew K · CIK 0001323190 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,407

SEC source: 0001395781-25-000002 · primary_doc.xml · nonDerivative · entry 2

Malave Luis · CIK 0001395781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,595

SEC source: 0001474506-25-000067 · primary_doc.xml · nonDerivative · entry 1

Balo Andrew K · CIK 0001323190 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,490

SEC source: 0001474506-25-000068 · primary_doc.xml · nonDerivative · entry 3

Danzig Allen · CIK 0001905433 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,922

SEC source: 0001474506-25-000066 · primary_doc.xml · nonDerivative · entry 3

Fischell Robert · CIK 0001557104 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,045

SEC source: 0001474506-25-000070 · primary_doc.xml · nonDerivative · entry 5

Carter Erin Catherine · CIK 0001993078 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,632

SEC source: 0001474506-25-000071 · primary_doc.xml · nonDerivative · entry 12

Malave Luis · CIK 0001395781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,617

SEC source: 0001474506-25-000072 · primary_doc.xml · nonDerivative · entry 3

BALLANTYNE JOHN · CIK 0001701346 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,126

SEC source: 0001993078-25-000003 · primary_doc.xml · nonDerivative · entry 1

Carter Erin Catherine · CIK 0001993078 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 762

SEC source: 0001323190-25-000003 · primary_doc.xml · nonDerivative · entry 1

Balo Andrew K · CIK 0001323190 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75

SEC source: 0001395781-25-000002 · primary_doc.xml · nonDerivative · entry 1

Malave Luis · CIK 0001395781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,395

SEC source: 0001622251-25-000002 · primary_doc.xml · nonDerivative · entry 1

Goode Paul · CIK 0001622251 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 339

F1 · kind: On October 7, 2022, the reporting person entered into an into Intellectual Property Purchase Agreement (the "IP Purchase Agreement") with Glucotrack, Inc. (the "Issuer"), pursuant to which the reporting person is entitled to certain specified milestone payments, payable in common stock, par value $0.001 per share, of the Issuer (the "Common Stock"), as set forth in the IP Purchase Agreement. Upon the achievement of the third milestone contemplated by the IP Purchase Agreement, the reporting person was issued 42 shares of Common Stock, pursuant to the terms of the IP Purchase Agreement.

F1 · price: On October 7, 2022, the reporting person entered into an into Intellectual Property Purchase Agreement (the "IP Purchase Agreement") with Glucotrack, Inc. (the "Issuer"), pursuant to which the reporting person is entitled to certain specified milestone payments, payable in common stock, par value $0.001 per share, of the Issuer (the "Common Stock"), as set forth in the IP Purchase Agreement. Upon the achievement of the third milestone contemplated by the IP Purchase Agreement, the reporting person was issued 42 shares of Common Stock, pursuant to the terms of the IP Purchase Agreement.

SEC source: 0001474506-25-000069 · primary_doc.xml · derivative · entry 10

Goode Paul · CIK 0001622251 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, par value $0.001 per share · 15,435 shares

Expires 2027-07-03

F6 · derivative.exercise_price: On November 14, 2024, in connection with the conversion of the Note, the reporting person was issued Series A common warrants (the "Series A Common Warrants") to purchase Common Stock and Series B common warrants (the "Series B Common Warrants") to purchase Common Stock, each with an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").

F7 · derivative.exercise_price: On March 12, 2025, the reporting person effected an Alternative Cashless Exercise of the Series B Common Warrants and exercised the warrants on a cashless basis via a warrant exchange for 15,435 shares of Common Stock.

F7 · kind: On March 12, 2025, the reporting person effected an Alternative Cashless Exercise of the Series B Common Warrants and exercised the warrants on a cashless basis via a warrant exchange for 15,435 shares of Common Stock.

SEC source: 0001474506-25-000069 · primary_doc.xml · nonDerivative · entry 3

Goode Paul · CIK 0001622251 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,989

F7 · kind: On March 12, 2025, the reporting person effected an Alternative Cashless Exercise of the Series B Common Warrants and exercised the warrants on a cashless basis via a warrant exchange for 15,435 shares of Common Stock.

SEC source: 0001474506-25-000070 · primary_doc.xml · derivative · entry 10

Carter Erin Catherine · CIK 0001993078 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, par value $0.001 per share · 40,297 shares

Expires 2027-07-03

F4 · derivative.exercise_price: On November 14, 2024, in connection with the conversion of the Note, the reporting person was issued Series A common warrants (the "Series A Common Warrants") to purchase Common Stock and Series B common warrants (the "Series B Common Warrants") to purchase Common Stock, each with an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").

F5 · derivative.exercise_price: On March 12, 2025, the reporting person effected an Alternative Cashless Exercise of the Series B Common Warrants and exercised the warrants on a cashless basis via a warrant exchange for 15,435 shares of Common Stock.

F5 · kind: On March 12, 2025, the reporting person effected an Alternative Cashless Exercise of the Series B Common Warrants and exercised the warrants on a cashless basis via a warrant exchange for 15,435 shares of Common Stock.

SEC source: 0001474506-25-000070 · primary_doc.xml · nonDerivative · entry 4

Carter Erin Catherine · CIK 0001993078 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,736

F5 · kind: On March 12, 2025, the reporting person effected an Alternative Cashless Exercise of the Series B Common Warrants and exercised the warrants on a cashless basis via a warrant exchange for 15,435 shares of Common Stock.

SEC source: 0001474506-25-000071 · primary_doc.xml · derivative · entry 17

Malave Luis · CIK 0001395781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, par value $0.001 per share · 133,532 shares

Expires 2027-07-03

F4 · derivative.exercise_price: On November 14, 2024, in connection with the conversion of the Note, the reporting person was issued Series A common warrants (the "Series A Common Warrants") to purchase Common Stock and Series B common warrants (the "Series B Common Warrants") to purchase Common Stock, each with an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").

F5 · derivative.exercise_price: On March 12, 2025, the reporting person effected an Alternative Cashless Exercise of the Series B Common Warrants and exercised the warrants on a cashless basis via a warrant exchange for 133,532 shares of Common Stock.

F5 · kind: On March 12, 2025, the reporting person effected an Alternative Cashless Exercise of the Series B Common Warrants and exercised the warrants on a cashless basis via a warrant exchange for 133,532 shares of Common Stock.

SEC source: 0001474506-25-000071 · primary_doc.xml · nonDerivative · entry 11

Malave Luis · CIK 0001395781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 141,541

F5 · kind: On March 12, 2025, the reporting person effected an Alternative Cashless Exercise of the Series B Common Warrants and exercised the warrants on a cashless basis via a warrant exchange for 133,532 shares of Common Stock.

SEC source: 0001474506-25-000073 · primary_doc.xml · derivative · entry 8

John A. Ballantyne Revocable Living Trust dated 08/01/2017 · CIK 0002046615 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, par value $0.001 per share · 2,560,553 shares

Expires 2027-07-03

F3 · derivative.exercise_price: On November 14, 2024, in connection with the Conversion, the Ballantyne Trust was issued Series A Common Warrants to purchase Common Stock and Series B Common Warrants to purchase Common Stock, each at an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").

F4 · derivative.exercise_price: On March 12, 2025, the Ballantyne Trust effected an Alternative Cashless Exercise of the Series B Common Warrants and exercised the warrants on a cashless basis via warrant exchange for 2,560,553 shares of Common Stock.

F4 · kind: On March 12, 2025, the Ballantyne Trust effected an Alternative Cashless Exercise of the Series B Common Warrants and exercised the warrants on a cashless basis via warrant exchange for 2,560,553 shares of Common Stock.

SEC source: 0001474506-25-000073 · primary_doc.xml · nonDerivative · entry 2

John A. Ballantyne Revocable Living Trust dated 08/01/2017 · CIK 0002046615 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,743,591

F4 · kind: On March 12, 2025, the Ballantyne Trust effected an Alternative Cashless Exercise of the Series B Common Warrants and exercised the warrants on a cashless basis via warrant exchange for 2,560,553 shares of Common Stock.

SEC source: 0001474506-25-000072 · primary_doc.xml · derivative · entry 9

BALLANTYNE JOHN · CIK 0001701346 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · John A. Ballantyne Rev Trust 08/01/2017

Disclosed balance after: 0

Underlying: Common Stock, par value $0.001 per share · 2,560,553 shares

Expires 2027-07-03

F4 · derivative.exercise_price: On November 14, 2024, in connection with the Conversion, the Ballantyne Trust was issued Series A Common Warrants to purchase Common Stock and Series B Common Warrants to purchase Common Stock, each at an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").

F5 · derivative.exercise_price: On March 12, 2025, the Ballantyne Trust effected an Alternative Cashless Exercise of the Series B Common Warrants and exercised the warrants on a cashless basis via warrant exchange for 2,560,553 shares of Common Stock.

F5 · kind: On March 12, 2025, the Ballantyne Trust effected an Alternative Cashless Exercise of the Series B Common Warrants and exercised the warrants on a cashless basis via warrant exchange for 2,560,553 shares of Common Stock.

F3 · ownership.direct: John A. Ballantyne is the trustee of the Ballantyne Trust and has sole voting and investment power over all securities owned by the Ballantyne Trust.

SEC source: 0001474506-25-000072 · primary_doc.xml · nonDerivative · entry 2

BALLANTYNE JOHN · CIK 0001701346 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · John A. Ballantyne Rev Trust 08/01/2017

Disclosed balance after: 2,743,591

F5 · kind: On March 12, 2025, the Ballantyne Trust effected an Alternative Cashless Exercise of the Series B Common Warrants and exercised the warrants on a cashless basis via warrant exchange for 2,560,553 shares of Common Stock.

F3 · ownership.direct: John A. Ballantyne is the trustee of the Ballantyne Trust and has sole voting and investment power over all securities owned by the Ballantyne Trust.

SEC source: 0001474506-25-000069 · primary_doc.xml · nonDerivative · entry 2

Goode Paul · CIK 0001622251 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,554

F8 · kind: On October 7, 2022, the reporting person entered into an into Intellectual Property Purchase Agreement (the "IP Purchase Agreement") with the issuer, pursuant to which the reporting person is entitled to certain specified milestone payments, payable in Common Stock, as set forth in the IP Purchase Agreement. Upon the achievement of the first and second milestones contemplated by the IP Purchase Agreement, the reporting person was issued 1,500 shares of Common Stock, pursuant to the terms of the IP Purchase Agreement.

F8 · price: On October 7, 2022, the reporting person entered into an into Intellectual Property Purchase Agreement (the "IP Purchase Agreement") with the issuer, pursuant to which the reporting person is entitled to certain specified milestone payments, payable in Common Stock, as set forth in the IP Purchase Agreement. Upon the achievement of the first and second milestones contemplated by the IP Purchase Agreement, the reporting person was issued 1,500 shares of Common Stock, pursuant to the terms of the IP Purchase Agreement.

SEC source: 0001474506-25-000069 · primary_doc.xml · derivative · entry 9

Goode Paul · CIK 0001622251 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 796

Underlying: Common Stock, par value $0.001 per share · 15,435 shares

Expires 2027-07-03

F6 · derivative.exercise_price: On November 14, 2024, in connection with the conversion of the Note, the reporting person was issued Series A common warrants (the "Series A Common Warrants") to purchase Common Stock and Series B common warrants (the "Series B Common Warrants") to purchase Common Stock, each with an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").

F6 · price: On November 14, 2024, in connection with the conversion of the Note, the reporting person was issued Series A common warrants (the "Series A Common Warrants") to purchase Common Stock and Series B common warrants (the "Series B Common Warrants") to purchase Common Stock, each with an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").

SEC source: 0001474506-25-000069 · primary_doc.xml · derivative · entry 8

Goode Paul · CIK 0001622251 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 796

Underlying: Common Stock, par value $0.001 per share · 796 shares

Expires 2030-01-03

F6 · price: On November 14, 2024, in connection with the conversion of the Note, the reporting person was issued Series A common warrants (the "Series A Common Warrants") to purchase Common Stock and Series B common warrants (the "Series B Common Warrants") to purchase Common Stock, each with an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").

SEC source: 0001474506-25-000069 · primary_doc.xml · derivative · entry 7

Goode Paul · CIK 0001622251 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock, par value $0.001 per share · 796 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: On November 14, 2024, the issuer completed a Qualified Financing and all outstanding principal and accrued but unpaid interest on the Note converted into Common Stock at the Floor Price.

F5 · derivative.exercise_date: On November 14, 2024, the issuer completed a Qualified Financing and all outstanding principal and accrued but unpaid interest on the Note converted into Common Stock at the Floor Price.

F5 · derivative.expiration_date: On November 14, 2024, the issuer completed a Qualified Financing and all outstanding principal and accrued but unpaid interest on the Note converted into Common Stock at the Floor Price.

SEC source: 0001474506-25-000069 · primary_doc.xml · nonDerivative · entry 1

Goode Paul · CIK 0001622251 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,054

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: On November 14, 2024, the issuer completed a Qualified Financing and all outstanding principal and accrued but unpaid interest on the Note converted into Common Stock at the Floor Price.

SEC source: 0001474506-25-000070 · primary_doc.xml · derivative · entry 9

Carter Erin Catherine · CIK 0001993078 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,078

Underlying: Common Stock, par value $0.001 per share · 40,297 shares

Expires 2027-07-03

F4 · derivative.exercise_price: On November 14, 2024, in connection with the conversion of the Note, the reporting person was issued Series A common warrants (the "Series A Common Warrants") to purchase Common Stock and Series B common warrants (the "Series B Common Warrants") to purchase Common Stock, each with an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").

F4 · price: On November 14, 2024, in connection with the conversion of the Note, the reporting person was issued Series A common warrants (the "Series A Common Warrants") to purchase Common Stock and Series B common warrants (the "Series B Common Warrants") to purchase Common Stock, each with an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").

SEC source: 0001474506-25-000070 · primary_doc.xml · derivative · entry 8

Carter Erin Catherine · CIK 0001993078 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,078

Underlying: Common Stock, par value $0.001 per share · 2,078 shares

Expires 2030-01-03

F4 · price: On November 14, 2024, in connection with the conversion of the Note, the reporting person was issued Series A common warrants (the "Series A Common Warrants") to purchase Common Stock and Series B common warrants (the "Series B Common Warrants") to purchase Common Stock, each with an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").

SEC source: 0001474506-25-000070 · primary_doc.xml · derivative · entry 7

Carter Erin Catherine · CIK 0001993078 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, par value $0.001 per share · 2,078 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: On November 14, 2024, the issuer completed a Qualified Financing and all outstanding principal and accrued but unpaid interest on the Note converted into common stock, par value $0.001 per share (the "Common Stock") at the Floor Price.

F1 · derivative.exercise_date: On July 18, 2024, the reporting person purchased a convertible promissory note in the principal amount of $50,000 (the "Note"). The Note bears simple interest at the rate of eight percent (8%) per annum and is due and payable in cash on the earlier of: (a) the twelve (12) month anniversary of Note, or (b) the date of closing of a Qualified Financing (defined below) (the "Maturity Date").

F2 · derivative.exercise_date: If not sooner repaid, all outstanding principal and accrued but unpaid interest on the Note (the "Note Balance"), as of the close of business on the day immediately preceding the date of the closing of the next issuance and sale of capital stock of the Company, in a single transaction or series of related transactions, to investors resulting in gross proceeds to the Company of at least $500,000 (excluding indebtedness converted in such financing) (a "Qualified Financing"), will automatically be converted into that number of shares of equity securities of the Company sold in the Qualified Financing equal to the number of shares calculated by dividing (X) the Note Balance by (Y) an amount equal to the price per share or other unit of equity securities issued in such Qualified Financing, and otherwise on the same terms as the security issued in the Qualified Financing, provided that the conversion price per share shall not be lower than $31.20 (the "Floor Price").

F1 · derivative.expiration_date: On July 18, 2024, the reporting person purchased a convertible promissory note in the principal amount of $50,000 (the "Note"). The Note bears simple interest at the rate of eight percent (8%) per annum and is due and payable in cash on the earlier of: (a) the twelve (12) month anniversary of Note, or (b) the date of closing of a Qualified Financing (defined below) (the "Maturity Date").

F2 · derivative.expiration_date: If not sooner repaid, all outstanding principal and accrued but unpaid interest on the Note (the "Note Balance"), as of the close of business on the day immediately preceding the date of the closing of the next issuance and sale of capital stock of the Company, in a single transaction or series of related transactions, to investors resulting in gross proceeds to the Company of at least $500,000 (excluding indebtedness converted in such financing) (a "Qualified Financing"), will automatically be converted into that number of shares of equity securities of the Company sold in the Qualified Financing equal to the number of shares calculated by dividing (X) the Note Balance by (Y) an amount equal to the price per share or other unit of equity securities issued in such Qualified Financing, and otherwise on the same terms as the security issued in the Qualified Financing, provided that the conversion price per share shall not be lower than $31.20 (the "Floor Price").

SEC source: 0001474506-25-000070 · primary_doc.xml · nonDerivative · entry 3

Carter Erin Catherine · CIK 0001993078 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,439

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: On November 14, 2024, the issuer completed a Qualified Financing and all outstanding principal and accrued but unpaid interest on the Note converted into common stock, par value $0.001 per share (the "Common Stock") at the Floor Price.

SEC source: 0001474506-25-000071 · primary_doc.xml · derivative · entry 16

Malave Luis · CIK 0001395781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,886

Underlying: Common Stock, par value $0.001 per share · 133,532 shares

Expires 2027-07-03

F4 · derivative.exercise_price: On November 14, 2024, in connection with the conversion of the Note, the reporting person was issued Series A common warrants (the "Series A Common Warrants") to purchase Common Stock and Series B common warrants (the "Series B Common Warrants") to purchase Common Stock, each with an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").

F4 · price: On November 14, 2024, in connection with the conversion of the Note, the reporting person was issued Series A common warrants (the "Series A Common Warrants") to purchase Common Stock and Series B common warrants (the "Series B Common Warrants") to purchase Common Stock, each with an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").

SEC source: 0001474506-25-000071 · primary_doc.xml · derivative · entry 15

Malave Luis · CIK 0001395781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,886

Underlying: Common Stock, par value $0.001 per share · 6,886 shares

Expires 2027-07-03

F4 · price: On November 14, 2024, in connection with the conversion of the Note, the reporting person was issued Series A common warrants (the "Series A Common Warrants") to purchase Common Stock and Series B common warrants (the "Series B Common Warrants") to purchase Common Stock, each with an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").

SEC source: 0001474506-25-000071 · primary_doc.xml · derivative · entry 14

Malave Luis · CIK 0001395781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, par value $0.001 per share · 6,886 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: On November 14, 2024, the issuer completed a Qualified Financing and all outstanding principal and accrued but unpaid interest on the Note converted into common stock, par value $0.001 per share (the "Common Stock") at the Floor Price.

F1 · derivative.exercise_date: On July 18, 2024, the reporting person purchased a convertible promissory note in the principal amount of $200,000 (the "Note"). The Note bears simple interest at the rate of eight percent (8%) per annum and is due and payable in cash on the earlier of: (a) the twelve (12) month anniversary of Note, or (b) the date of closing of a Qualified Financing (defined below) (the "Maturity Date").

F2 · derivative.exercise_date: If not sooner repaid, all outstanding principal and accrued but unpaid interest on the Note (the "Note Balance"), as of the close of business on the day immediately preceding the date of the closing of the next issuance and sale of capital stock of the Company, in a single transaction or series of related transactions, to investors resulting in gross proceeds to the Company of at least $500,000 (excluding indebtedness converted in such financing) (a "Qualified Financing"), will automatically be converted into that number of shares of equity securities of the Company sold in the Qualified Financing equal to the number of shares calculated by dividing (X) the Note Balance by (Y) an amount equal to the price per share or other unit of equity securities issued in such Qualified Financing, and otherwise on the same terms as the security issued in the Qualified Financing, provided that the conversion price per share shall not be lower than $31.20 (the "Floor Price").

F1 · derivative.expiration_date: On July 18, 2024, the reporting person purchased a convertible promissory note in the principal amount of $200,000 (the "Note"). The Note bears simple interest at the rate of eight percent (8%) per annum and is due and payable in cash on the earlier of: (a) the twelve (12) month anniversary of Note, or (b) the date of closing of a Qualified Financing (defined below) (the "Maturity Date").

F2 · derivative.expiration_date: If not sooner repaid, all outstanding principal and accrued but unpaid interest on the Note (the "Note Balance"), as of the close of business on the day immediately preceding the date of the closing of the next issuance and sale of capital stock of the Company, in a single transaction or series of related transactions, to investors resulting in gross proceeds to the Company of at least $500,000 (excluding indebtedness converted in such financing) (a "Qualified Financing"), will automatically be converted into that number of shares of equity securities of the Company sold in the Qualified Financing equal to the number of shares calculated by dividing (X) the Note Balance by (Y) an amount equal to the price per share or other unit of equity securities issued in such Qualified Financing, and otherwise on the same terms as the security issued in the Qualified Financing, provided that the conversion price per share shall not be lower than $31.20 (the "Floor Price").

SEC source: 0001474506-25-000071 · primary_doc.xml · nonDerivative · entry 10

Malave Luis · CIK 0001395781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,009

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: On November 14, 2024, the issuer completed a Qualified Financing and all outstanding principal and accrued but unpaid interest on the Note converted into common stock, par value $0.001 per share (the "Common Stock") at the Floor Price.

SEC source: 0001474506-25-000073 · primary_doc.xml · derivative · entry 7

John A. Ballantyne Revocable Living Trust dated 08/01/2017 · CIK 0002046615 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,036

Underlying: Common Stock, par value $0.001 per share · 2,560,553 shares

Expires 2027-07-03

F3 · derivative.exercise_price: On November 14, 2024, in connection with the Conversion, the Ballantyne Trust was issued Series A Common Warrants to purchase Common Stock and Series B Common Warrants to purchase Common Stock, each at an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").

F3 · price: On November 14, 2024, in connection with the Conversion, the Ballantyne Trust was issued Series A Common Warrants to purchase Common Stock and Series B Common Warrants to purchase Common Stock, each at an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").

SEC source: 0001474506-25-000073 · primary_doc.xml · derivative · entry 6

John A. Ballantyne Revocable Living Trust dated 08/01/2017 · CIK 0002046615 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,036

Underlying: Common Stock, par value $0.001 per share · 132,036 shares

Expires 2030-01-03

F3 · price: On November 14, 2024, in connection with the Conversion, the Ballantyne Trust was issued Series A Common Warrants to purchase Common Stock and Series B Common Warrants to purchase Common Stock, each at an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").

SEC source: 0001474506-25-000073 · primary_doc.xml · nonDerivative · entry 1

John A. Ballantyne Revocable Living Trust dated 08/01/2017 · CIK 0002046615 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 183,039

F1 · kind: On July 30, 2024, the issuer entered into a convertible promissory note and three warrant agreements (the "Warrants") with the John A. Ballantyne Rev Trust 08/01/2017 (the "Ballantyne Trust"), providing for the private placement of a secured convertible promissory note in the aggregate principal amount of $4,000,000 (the "Note"). The Note did not have a fixed conversion price, and the conversion price was dependent on the market price of the issuer's common stock, par value $0.001 per share (the "Common Stock").

F2 · kind: On November 14, 2024, the issuer completed a public offering (the "Offering"). In connection with the Offering, the Ballantyne Trust agreed to convert approximately $4,093,112 of debt, which represented the outstanding principal and accrued interest under the Note, on substantially the same terms as the Offering, resulting in the issuance of 132,036 shares of Common Stock (plus 132,036 accompanying Series A common warrants (the "Series A Common Warrants") and 132,036 accompanying Series B common warrants (the "Series B Common Warrants")), based on a conversion price of $31.00 per share (the "Conversion"), which is equal to the consolidated closing bid price of the Common Stock on the Nasdaq Capital Market on November 12, 2024, the day prior to the date the securities purchase agreement governing the Conversion was executed.

SEC source: 0001474506-25-000072 · primary_doc.xml · derivative · entry 8

BALLANTYNE JOHN · CIK 0001701346 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · John A. Ballantyne Rev Trust 08/01/2017

Disclosed balance after: 132,036

Underlying: Common Stock, par value $0.001 per share · 2,560,553 shares

Expires 2027-07-03

F4 · derivative.exercise_price: On November 14, 2024, in connection with the Conversion, the Ballantyne Trust was issued Series A Common Warrants to purchase Common Stock and Series B Common Warrants to purchase Common Stock, each at an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").

F4 · price: On November 14, 2024, in connection with the Conversion, the Ballantyne Trust was issued Series A Common Warrants to purchase Common Stock and Series B Common Warrants to purchase Common Stock, each at an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").

F3 · ownership.direct: John A. Ballantyne is the trustee of the Ballantyne Trust and has sole voting and investment power over all securities owned by the Ballantyne Trust.

SEC source: 0001474506-25-000072 · primary_doc.xml · derivative · entry 7

BALLANTYNE JOHN · CIK 0001701346 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · John A. Ballantyne Rev Trust 08/01/2017

Disclosed balance after: 132,036

Underlying: Common Stock, par value $0.001 per share · 132,036 shares

Expires 2030-01-03

F4 · price: On November 14, 2024, in connection with the Conversion, the Ballantyne Trust was issued Series A Common Warrants to purchase Common Stock and Series B Common Warrants to purchase Common Stock, each at an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").

F3 · ownership.direct: John A. Ballantyne is the trustee of the Ballantyne Trust and has sole voting and investment power over all securities owned by the Ballantyne Trust.

SEC source: 0001474506-25-000072 · primary_doc.xml · nonDerivative · entry 1

BALLANTYNE JOHN · CIK 0001701346 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · John A. Ballantyne Rev Trust 08/01/2017

Disclosed balance after: 183,039

F1 · kind: On July 30, 2024, the issuer entered into a convertible promissory note and three warrant agreements (the "Warrants") with the John A. Ballantyne Rev Trust 08/01/2017 (the "Ballantyne Trust"), providing for the private placement of a secured convertible promissory note in the aggregate principal amount of $4,000,000 (the "Note"). The Note did not have a fixed conversion price, and the conversion price was dependent on the market price of the issuer's common stock, par value $0.001 per share (the "Common Stock").

F2 · kind: On November 14, 2024, the issuer completed a public offering (the "Offering"). In connection with the Offering, the Ballantyne Trust agreed to convert approximately $4,093,112 of debt, which represented the outstanding principal and accrued interest under the Note, on substantially the same terms as the Offering, resulting in the issuance of 132,036 shares of Common Stock (plus 132,036 accompanying Series A common warrants (the "Series A Common Warrants") and 132,036 accompanying Series B common warrants (the "Series B Common Warrants")), based on a conversion price of $31.00 per share (the "Conversion"), which is equal to the consolidated closing bid price of the Common Stock on the Nasdaq Capital Market on November 12, 2024, the day prior to the date the securities purchase agreement governing the Conversion was executed.

F3 · ownership.direct: John A. Ballantyne is the trustee of the Ballantyne Trust and has sole voting and investment power over all securities owned by the Ballantyne Trust.

SEC source: 0001474506-25-000073 · primary_doc.xml · derivative · entry 5

John A. Ballantyne Revocable Living Trust dated 08/01/2017 · CIK 0002046615 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,260

Underlying: Common Stock, par value $0.001 per share · 59,260 shares

Expires 2034-07-30

F1 · kind: On July 30, 2024, the issuer entered into a convertible promissory note and three warrant agreements (the "Warrants") with the John A. Ballantyne Rev Trust 08/01/2017 (the "Ballantyne Trust"), providing for the private placement of a secured convertible promissory note in the aggregate principal amount of $4,000,000 (the "Note"). The Note did not have a fixed conversion price, and the conversion price was dependent on the market price of the issuer's common stock, par value $0.001 per share (the "Common Stock").

F2 · kind: On November 14, 2024, the issuer completed a public offering (the "Offering"). In connection with the Offering, the Ballantyne Trust agreed to convert approximately $4,093,112 of debt, which represented the outstanding principal and accrued interest under the Note, on substantially the same terms as the Offering, resulting in the issuance of 132,036 shares of Common Stock (plus 132,036 accompanying Series A common warrants (the "Series A Common Warrants") and 132,036 accompanying Series B common warrants (the "Series B Common Warrants")), based on a conversion price of $31.00 per share (the "Conversion"), which is equal to the consolidated closing bid price of the Common Stock on the Nasdaq Capital Market on November 12, 2024, the day prior to the date the securities purchase agreement governing the Conversion was executed.

F1 · price: On July 30, 2024, the issuer entered into a convertible promissory note and three warrant agreements (the "Warrants") with the John A. Ballantyne Rev Trust 08/01/2017 (the "Ballantyne Trust"), providing for the private placement of a secured convertible promissory note in the aggregate principal amount of $4,000,000 (the "Note"). The Note did not have a fixed conversion price, and the conversion price was dependent on the market price of the issuer's common stock, par value $0.001 per share (the "Common Stock").

F2 · price: On November 14, 2024, the issuer completed a public offering (the "Offering"). In connection with the Offering, the Ballantyne Trust agreed to convert approximately $4,093,112 of debt, which represented the outstanding principal and accrued interest under the Note, on substantially the same terms as the Offering, resulting in the issuance of 132,036 shares of Common Stock (plus 132,036 accompanying Series A common warrants (the "Series A Common Warrants") and 132,036 accompanying Series B common warrants (the "Series B Common Warrants")), based on a conversion price of $31.00 per share (the "Conversion"), which is equal to the consolidated closing bid price of the Common Stock on the Nasdaq Capital Market on November 12, 2024, the day prior to the date the securities purchase agreement governing the Conversion was executed.

SEC source: 0001474506-25-000073 · primary_doc.xml · derivative · entry 4

John A. Ballantyne Revocable Living Trust dated 08/01/2017 · CIK 0002046615 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,191

Underlying: Common Stock, par value $0.001 per share · 76,191 shares

Expires 2034-07-30

F1 · kind: On July 30, 2024, the issuer entered into a convertible promissory note and three warrant agreements (the "Warrants") with the John A. Ballantyne Rev Trust 08/01/2017 (the "Ballantyne Trust"), providing for the private placement of a secured convertible promissory note in the aggregate principal amount of $4,000,000 (the "Note"). The Note did not have a fixed conversion price, and the conversion price was dependent on the market price of the issuer's common stock, par value $0.001 per share (the "Common Stock").

F2 · kind: On November 14, 2024, the issuer completed a public offering (the "Offering"). In connection with the Offering, the Ballantyne Trust agreed to convert approximately $4,093,112 of debt, which represented the outstanding principal and accrued interest under the Note, on substantially the same terms as the Offering, resulting in the issuance of 132,036 shares of Common Stock (plus 132,036 accompanying Series A common warrants (the "Series A Common Warrants") and 132,036 accompanying Series B common warrants (the "Series B Common Warrants")), based on a conversion price of $31.00 per share (the "Conversion"), which is equal to the consolidated closing bid price of the Common Stock on the Nasdaq Capital Market on November 12, 2024, the day prior to the date the securities purchase agreement governing the Conversion was executed.

F1 · price: On July 30, 2024, the issuer entered into a convertible promissory note and three warrant agreements (the "Warrants") with the John A. Ballantyne Rev Trust 08/01/2017 (the "Ballantyne Trust"), providing for the private placement of a secured convertible promissory note in the aggregate principal amount of $4,000,000 (the "Note"). The Note did not have a fixed conversion price, and the conversion price was dependent on the market price of the issuer's common stock, par value $0.001 per share (the "Common Stock").

F2 · price: On November 14, 2024, the issuer completed a public offering (the "Offering"). In connection with the Offering, the Ballantyne Trust agreed to convert approximately $4,093,112 of debt, which represented the outstanding principal and accrued interest under the Note, on substantially the same terms as the Offering, resulting in the issuance of 132,036 shares of Common Stock (plus 132,036 accompanying Series A common warrants (the "Series A Common Warrants") and 132,036 accompanying Series B common warrants (the "Series B Common Warrants")), based on a conversion price of $31.00 per share (the "Conversion"), which is equal to the consolidated closing bid price of the Common Stock on the Nasdaq Capital Market on November 12, 2024, the day prior to the date the securities purchase agreement governing the Conversion was executed.